Pfizer shares slump as forecasts miss expectations.
Pfizer shares fell in pre-market trade on Tuesday after its Covid vaccines and antiviral pill forecasts missed analysts’ expectations.
Source: Sharecast
The drug maker said it expects to report 2022 revenues for its Covid-19 vaccine Comirnaty of $32bn, while sales of its oral antiviral for Covid, Paxlovid, are expected to come in at $22bn. Analysts had been expecting just under $34bn in revenue for the vaccines and $23bn for Paxlovid.
Pfizer expects overall 2022 revenues of between $98bn and $102bn, while adjusted diluted earnings per share are forecast at between $6.35 and $6.55.
The company said fourth-quarter revenues rose 105% on the year to $23.8bn, compared to expectations of around $24bn, while adjusted earnings came in at $1.08, versus forecasts of $0.87. Comirnaty accounted for $12.5bn of sales during the fourth quarter.
At 1330 GMT, the shares were down 3.7% in pre-market trade at $51.22.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
